Skip to content

A Randomized Double-Blind Trial of Likaneng Chewable Tablets for Weight Management and Glycemic Control

A Randomized Double-Blind Trial of Likaneng Chewable Tablets for Weight Management and Glycemic Control

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123402
Enrollment
Unknown
Registered
2026-04-26
Start date
2026-04-27
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Experimental group:Take 2 tablets of Likaten Chewy Candies, chewed 30 minutes before lunch and dinner or with meals, for a continuous intervention of 2 months.
Control group:The placebo will be identical to Likaten Chewable Candies in color, odor, and taste. Take 2 placebo tablets each time, chewed 30 minutes before lunch and dinner or with meals, for a cont

Sponsors

Yibin Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Permanent residents of Yibin City who have lived there for more than one year; 2. Age between 18 and 40 years old; 3. BMI within the range of 24 to 30 kg/m^2; 4. No other weight loss-related treatments were performed within the past 6 months before treatment.

Exclusion criteria

Exclusion criteria: 1. Pregnant women, lactating women, or those planning to get pregnant within the next 6 months; 2. Those with secondary obesity due to conditions such as hypothyroidism or hypercortisolism; 3. Patients with severe cardiovascular or cerebrovascular diseases, abnormal liver or kidney function, digestive tract diseases, tumors, infectious diseases or mental disorders; 4. Patients with a clear diagnosis of diabetes or those using oral medications or insulin for treatment; 5. People who have received probiotic, antibiotic or hormone treatment in the past month; 6. Those allergic to beans; 7. Those who are unable or refuse to answer questions during the survey.

Design outcomes

Primary

MeasureTime frame
Percentage of body weight change at the 8th week of intervention;

Secondary

MeasureTime frame
Body weight at the 8th week of intervention;Proportion of weight loss at the 8th week of intervention;Chamges in body composition at Week 2,Week 4 and Week 8 of intervention compared with baseline values;Body weight at Week 12 of intervention;Percentage change in body weight from baseline at Week 12 of intervention;

Countries

China

Contacts

Public ContactLihua Zheng

Yibin Second People's Hospital

362436778@qq.com+86 158 8135 8296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026